Sweden's NeuroNova has identified a convenient and accessible source of neural stem cells in the ependymal layer of the brain. The company hopes to use such cells for transplantation therapy in Parkinson's disease and as a platform for drug discovery.
S-11433 Stockholm, Sweden
Phone: (46) 8786 0901
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
Gilead’s Kite division presented Phase I data for its next-generation CAR-T therapy KITE-363 in patients with B-cell lymphomas.
